Recruiting
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
NCT07717411· Phase 3· Hoffmann-La Roche· Source
Recruiting
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
NCT07863999· Phase 3· Shanghai Pulmonary Hospital, Shanghai, China· Source
Contact: Yongxin Zhou, PhD
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428· Phase 3· Hutchmed· Source
Contact: Ping Li
Not yet recruiting
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Ping Li, Doctor
Recruiting
Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
NCT06967038· Phase 1/2· Bangdong Gong· Source
Contact: Bangdong Gong, doctor
Recruiting
Clinical Study of U01(ssCART-19) in Patients With B-Cell Lymphoma
NCT07093073· Phase 1· Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd· Source
Contact: Wenjun Zhang, Ph.D
Recruiting
Multicenter iTBS Neuromodulation for PTSD Treatment
NCT06434766· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source
Contact: Xinchun Mei
Active, not recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· Phase 3· Pfizer· Source
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Xijin Wang, Site 7028
Recruiting
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
NCT06450067· Juventas Cell Therapy Ltd.· Source
Contact: Aibin Liang, Dr.
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995· Phase 3· Eli Lilly and Company· Source
Contact: Shaoqing Yu (principal investigator)
Recruiting
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
NCT06387069· Phase 3· Hutchmed· Source
Contact: Jianfei Fu
Recruiting
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456· Phase 3· Ascentage Pharma Group Inc.· Source
Contact: Jianfei Fu, M.D., Ph.D.
Active, not recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
NCT06081647· RenJi Hospital· Source
Contact: Jianhui Liu
Recruiting
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
NCT06182696· Phase 1/2· OriCell Therapeutics Co., Ltd.· Source
Contact: Aibin Liang
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
NCT05954910· Hoffmann-La Roche· Source
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Xijin Wang, Site 7028
Active, not recruiting
Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
NCT06175351· Phase 1/2· Mabwell (Shanghai) Bioscience Co., Ltd.· Source
Recruiting
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
NCT05866029· Peking Union Medical College Hospital· Source
Contact: Keqin Zhang
Active, not recruiting
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
NCT06295679· Amgen· Source
Active, not recruiting
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04684147· Phase 2· Juventas Cell Therapy Ltd.· Source
Contact: Aibin Liang
Active, not recruiting
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· Phase 3· Epizyme, Inc.· Source
Active, not recruiting
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source